Exploring the Molecular Basis to Healthy Obesity: The Diabetes Risk Assessment Study
NCT ID: NCT01884714
Last Updated: 2016-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2011-07-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Rural OPTIFAST Intervention for Partial Remission of Type 2 Diabetes in Adults With Obesity
NCT04764279
Explorative Assessment of Biomarkers in Overweight and Obese Subjects
NCT01910051
Type 2 Diabetes Remission
NCT06177210
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
NCT05165706
Dietary Fatty Acid Composition and Obesity-related Metabolic Abnormalities
NCT01451970
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
RATIONALE: Type-2 diabetes is a disease state that affects multiple organs of the biological system, including alterations in adipocyte and muscle insulin signalling, hepatic glucose production, glucose absorption from the gastrointestinal tract, and pancreatic insulin deficiency caused by the loss of β-cell mass and function. Understanding the molecular communication taking place both within and between these tissues is paramount to unravel the metabolic regulatory networks and mechanisms underlying diabetes. Global gene expression profiling (i.e. transcriptomics) and metabolite profiling (i.e. metabolomics) offer powerful approaches to understand the biological processes associated with diabetes and obesity. The analysis of gene expression profiles provides an opportunity to identify early markers of metabolic dysregulation. In contrast, metabolites represent an endpoint of gene and protein function; thus metabolomics is ideally suited for the identification of biomarkers that reflect the biochemical processes underlying a physiological state. By integrating gene expression profiling with metabolite profiling, we will have the opportunity to improve our understanding of the metabolic perturbations related to obesity and/or type-2 diabetes.
OBJECTIVES: The specific goals of this project are to:
1. Recruit a sample of lean, lean/diabetic, obese, and obese/diabetic research participants from the Guelph community.
2. Assess blood glucose and insulin levels in these 4 groups both at baseline and after the consumption of a standardized high fat/high calorie meal.
3. Define the metabotype of these 4 groups by profiling plasma metabolites with mass spectrometry. The current study will examine only blood metabolites.
4. Define subcutaneous adipose tissue gene expression profiles of these 4 groups using microarray technology.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High fat/high calorie meal
All subjects are provided a high calorie (\~1300kcal) and high fat (\~60g fat) breakfast meal.
High fat/high calorie meal
All subjects are provided a high calorie (\~1300kcal) and high fat (\~60g fat) breakfast meal.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High fat/high calorie meal
All subjects are provided a high calorie (\~1300kcal) and high fat (\~60g fat) breakfast meal.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Infectious diseases
* Viral infection
* Cancer
* Alcohol consumption (i.e. more than 2 drinks/day, where 1 drink = 10 g alcohol).
35 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Public Health Agency of Canada (PHAC)
OTHER_GOV
University of Guelph
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
David M Mutch
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David M Mutch, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Guelph
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Guelph, Human Nutraceutical Research Unit
Guelph, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Perreault M, Zulyniak MA, Badoud F, Stephenson S, Badawi A, Buchholz A, Mutch DM. A distinct fatty acid profile underlies the reduced inflammatory state of metabolically healthy obese individuals. PLoS One. 2014 Feb 10;9(2):e88539. doi: 10.1371/journal.pone.0088539. eCollection 2014.
Badoud F, Lam KP, DiBattista A, Perreault M, Zulyniak MA, Cattrysse B, Stephenson S, Britz-McKibbin P, Mutch DM. Serum and adipose tissue amino acid homeostasis in the metabolically healthy obese. J Proteome Res. 2014 Jul 3;13(7):3455-66. doi: 10.1021/pr500416v. Epub 2014 Jun 23.
Badoud F, Lam KP, Perreault M, Zulyniak MA, Britz-McKibbin P, Mutch DM. Metabolomics Reveals Metabolically Healthy and Unhealthy Obese Individuals Differ in their Response to a Caloric Challenge. PLoS One. 2015 Aug 14;10(8):e0134613. doi: 10.1371/journal.pone.0134613. eCollection 2015.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10AP033
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.